Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP). NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP), 2019, version number 2, NCCP National SACT Regimen, NCCP, viewed 16/10/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab Vedotin, Cisplatin, Cytarabine, Etoposide |